Birchbrook Inc. Sells 15,107 Shares of Bristol Myers Squibb Company $BMY

Birchbrook Inc. reduced its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 94.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 885 shares of the biopharmaceutical company’s stock after selling 15,107 shares during the period. Birchbrook Inc.’s holdings in Bristol Myers Squibb were worth $51,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. waypoint wealth counsel acquired a new position in Bristol Myers Squibb during the 4th quarter worth $1,194,000. Life Cycle Investment Partners Ltd bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $34,406,000. Lazard Asset Management LLC raised its position in shares of Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after acquiring an additional 368,193 shares during the last quarter. Axxcess Wealth Management LLC lifted its stake in shares of Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after acquiring an additional 21,196 shares during the period. Finally, Asset One Wealth Management LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at about $4,075,000. Institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Analyst Ratings Changes

A number of analysts recently commented on BMY shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday. They set an “overweight” rating for the company. Truist Financial reissued a “buy” rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Trading Up 0.7%

NYSE BMY opened at $64.63 on Friday. The stock has a 50-day simple moving average of $58.71 and a 200 day simple moving average of $58.64. The company has a market capitalization of $132.02 billion, a PE ratio of 14.24, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.96 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. Bristol Myers Squibb’s payout ratio is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.